title: Pulmonary hypertension in thoracic surgical patients.
abstract: OBJECTIVE
  Literature about thoracic surgery in patients with pulmonary hypertension is scarce. Perceived high risk has appropriately discouraged any unnecessary operation. However, the medical therapy for pulmonary hypertension has made great advances during the last decade. It is likely that future advances in survival and possibly the need for diagnostic procedures will increase the anesthesiologist's exposure to such patients. Understanding the unique physiology as well as new therapeutic agents will facilitate safe care for these challenging patients.
  
  
  RESULTS
  Since 1998, there have been three World Heath Organization symposiums on pulmonary hypertension. The most recent meeting in 2008 at Dana Point included revisions of the classification scheme and updates on new trials and therapies. New drugs have been utilized in cardiac, lung, or liver transplant operations to treat pulmonary hypertension. It is also recognized that one-lung ventilation presents unique problems for the patient with pulmonary hypertension. Inhalation use of the new pulmonary vasodilator drugs represents a new frontier for intraoperative pharmacology.
  
  
  CONCLUSIONS
  Here, the various types of pulmonary hypertension, physiologic changes, and new drug therapies are reviewed. Clinical experience with patients with pulmonary hypertension undergoing both nonthoracic and thoracic procedures is also reviewed. By identifying potential problem areas and application of new pharmacology, an approach to the patient with pulmonary hypertension is synthesized.
authors.affiliation: Department of Anesthesia, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA. alan-ross@uiowa.edu
authors.forename: Alan F
authors.initials: AF
authors.lastname: Ross
authors.forename: Kenichi
authors.initials: K
authors.lastname: Ueda
mesh_terms: D000769:Anesthesia, Inhalation / Q000379:methods*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D000077300:Bosentan; D065130:Endothelin A Receptor Antagonists; D065131:Endothelin B Receptor Antagonists; D011464:Epoprostenol / Q000627:therapeutic use*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000145:classification / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use; D011687:Purines / Q000627:therapeutic use; D000068677:Sildenafil Citrate; D013449:Sulfonamides / Q000627:therapeutic use; D013450:Sulfones / Q000627:therapeutic use; D019616:Thoracic Surgical Procedures / Q000379:methods*; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D000959:Antihypertensive Agents; D065130:Endothelin A Receptor Antagonists; D065131:Endothelin B Receptor Antagonists; D010879:Piperazines; D011687:Purines; D013449:Sulfonamides; D013450:Sulfones; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate; D011464:Epoprostenol; D000077300:Bosentan